4-甲基-2-甲硫基嘧啶-5-甲酸乙酯 | 7234-25-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-甲基-2-甲硫基嘧啶-5-甲酸乙酯
• 中文别名: 4-甲基-2-甲硫基-嘧啶-5-甲酸乙酯；2-(甲硫基)-4-甲基-5-嘧啶甲酸乙酯；2-甲基硫代-4-甲基-5-嘧啶羧酸乙酯；4-甲基-2-(甲硫基)嘧啶-5-羧酸乙酯
• 英文名称: ethyl 4-methyl-2-(methylthio)pyrimidine-5-carboxylate
• 英文别名: 4-methyl-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester；ethyl 4-methyl-2-(methylthio)pyrimidin-5-carboxylate；ethyl 4-methyl-2-methylsulfanyl-pyrimidine-5-carboxylate；4-Methyl-2-methyl-mercaptopyrimidin-carbonsaeure-(5)-ethylester；ethyl 4-methyl-2-methylsulfanylpyrimidine-5-carboxylate
• CAS: 7234-25-5
• 化学式: C₉H₁₂N₂O₂S
• 分子量: 212.272
• InChiKey: LJDJKDAPYUXBPE-UHFFFAOYSA-N

物化性质

• 熔点：
  59-60 °C
• 沸点：
  322.1±22.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  77.4
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 安全说明：
  S36/37
• 危险类别码：
  R20/22
• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H320,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 4-methyl-2-(methylthio)pyrimidine-5-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 4-methyl-2-(methylthio)pyrimidine-5-carboxylate
CAS number: 7234-25-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H12N2O2S
Molecular weight: 212.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲基-2-甲硫基嘧啶-5-甲酸乙酯 在 sodium hydroxide 作用下， 反应 30.0h， 生成 4-甲基-2-甲硫基嘧啶
  参考文献：
  名称：

  Sansebastiano; Mosti; Menozzi, Il Farmaco, 1993, vol. 48, # 3, p. 335 - 355

  摘要：

  DOI：
• 作为产物：
  描述：

  1,4-二氢-4-异丙基-6-甲基-2-(甲硫基)嘧啶-5-羧酸乙酯 在 碘苯二乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以69%的产率得到4-甲基-2-甲硫基嘧啶-5-甲酸乙酯
  参考文献：
  名称：

  使用（二乙酰氧基碘）苯进行4-取代-1,4-二氢嘧啶的轻度和高效氧化芳构化

  摘要：

  4-烷基或芳基-1,4-二氢嘧啶很容易在温和的反应条件下被（二乙酰氧基碘）苯氧化为相应的嘧啶衍生物，收率很好。J.杂环化​​学。（2010）。

  DOI：

  10.1002/jhet.389

文献信息

• PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2
  申请人：EFFECTOR THERAPEUTICS, INC.

  公开号：US20170121339A1

  公开（公告）日：2017-05-04

  The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , W 1 , R 1 , R 2 , R 3 , R 4 , R 5a , R 5b , R 6 , R 7 , R 7a , R 7b , R 8 , R 8a , R 8b , R 9 , R 9a , R 9b and R 10 and subscripts “m” and “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

  本发明提供了根据式I合成的化合物、药用可接受的配方以及用途，或者其立体异构体、互变异构体或药用可接受的盐。对于式I化合物A1、A2、A3、A4、A5、A6、A7、W1、R1、R2、R3、R4、R5a、R5b、R6、R7、R7a、R7b、R8、R8a、R8b、R9、R9a、R9b和R10以及下标“m”和“n”的定义如规范中所述。这些创新的式I化合物是Mnk的抑制剂，并在许多治疗应用中发挥作用，包括但不限于治疗炎症和各种癌症。
• PYRIDOPYRIMIDINONE INHIBITORS OF KINASES
  申请人：AbbVie Inc.

  公开号：US20130225589A1

  公开（公告）日：2013-08-29

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1 , R 2 , R 3 , R 4 , and B are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

  本发明涉及式(I)化合物或药理可接受的盐，其中R1、R2、R3、R4和B在描述中定义。本发明还涉及包含所述化合物的组合物，这些化合物可用于抑制诸如wee-1的激酶，以及治疗诸如癌症疾病的方法。
• [EN] PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDOPYRIMIDINE EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：MERCK PATENT GMBH

  公开号：WO2014023385A1

  公开（公告）日：2014-02-13

  Compounds of the formula (I) in which R, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus

  化合物的结构式（I），其中R，R1和R2具有权利要求1中指示的含义，是Syk的抑制剂，可用于治疗癌症、类风湿性关节炎和/或系统性红斑狼疮。
• [EN] 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER<br/>[FR] PYRIDO[4,3-D]PYRIMIDINES 2,5-DIAMINO-SUBSTITUÉES EN TANT QU'INHIBITEURS D'AUTOTAXINE CONTRE LE CANCER
  申请人：MERCK PATENT GMBH

  公开号：WO2010063352A1

  公开（公告）日：2010-06-10

  The present invention relates to pyridopyrimidine derivatives according to formula (I), as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.

  本发明涉及按照式(I)的吡啶吡嘧啶衍生物，作为自体毒素抑制剂，并且利用这类化合物用于治疗和/或预防由增加的溶磷脂酸水平和/或自体毒素的激活引起、介导和/或传播的生理和/或病理条件，特别是不同癌症。
• [EN] TAM KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES TAM
  申请人：SYROS PHARMACEUTICALS INC

  公开号：WO2019014513A1

  公开（公告）日：2019-01-17

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat diseases, such as cancer.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及利用这种化合物治疗疾病（如癌症）的方法。